Not yet recruitingPhase 3NCT07261150

Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)

Studying Histoplasmosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Minnesota
Principal Investigator: Nathan Bahr, MD
University of Minnesota
Intervention: LAmB B(drug)
Enrollment: 664 target
Eligibility: 18 years · All sexes
Timeline: 2026 – 2030

Study locations (2)

University of Minnesota, Minneapolis, Minnesota, United States
Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil

Collaborators

Federal University of Health Science of Porto Alegre

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07261150 on ClinicalTrials.gov

Other trials for Histoplasmosis

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT05814432
Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS
Federal University of Health Science of Porto Alegre

See all trials for Histoplasmosis →

← Back to all trials